Sarcoma encompasses >70 subtypes of mesenchymal origin, constituting 1-2% of all cancers. From a biological perspective, sarcomas can be classified into two broad categories: sarcomas driven by simple genetic alterations, such as translocations or specific activating mutations; and those with complex and unbalanced genomic profiles. Both include a broad diversity of entities, often with very different molecular characteristics, course of disease and therapeutic implications. Our group focuses on sarcoma translational research, with an emphasis on biological understanding of sarcomas oriented to biomarker and drug development.
Among these, gastrointestinal stromal tumors (GISTs) represent the most common malignant mesenchymal neoplasm and constitutes a paradigm model for studying oncogene addiction and identifying structural and functional mechanisms of response and resistance to treatment. In recent years, our work has advanced the understanding of the pathophysiological mechanisms of GIST and exposed critical insights on the complex evolution of KIT/PDGFRA driver mutations leading to therapy resistance through comprehensive analyses of tissue and liquid biopsy samples. Currently ongoing efforts on GIST include: 1) The GISTomics project—a European initiative led by our group—aims to advance insights into the landscape of GIST evolution; and 2) A real-world-based genomic and transcriptomic landscape in a cohort of 1,427 GIST cases, the largest series available to date. Leveraging our GIST knowledge, and thanks to funding received from the CRIS Excellence Program, we are expanding these insights into the broad spectrum of malignant neoplasms of mesenchymal origin, with a focus on chromosome instability (CIN).
As part of our translational efforts, we pursue the identification of critical molecular mediators of therapeutic adaptation and resistance in GIST. Our work involves the discovery and functional characterization of key molecular events that can be potentially targetable. These mediators range from signaling intermediates, to the unfolded protein response (UPR) and interactions with the tissue microenvironment (TME), all of which are involved in the sensitivity/resistance to KIT inhibition. In this sense, César Serrano’s twin lab at the Institute for Research in Biomedicine (IRB), within the TRIP Clinics program, expands these views to the fields of protein degradation and the ubiquitin-proteasome system. Additionally, we leverage multi-omic datasets to identify and characterize the patterns of progression of previously uncharacterized sarcoma subtypes.
Our aim is to have a true clinical impact by improving the daily treatment and care of our patients. We are proud that our Sarcoma Multidisciplinary Unit is a Spanish Health Ministry-designed referral center (CSUR), and we belong to the European Reference Network ERN-EURACAN, which therefore constitutes an optimal setting for translating cancer discovery into clinical benefits. In this sense, three highlights from 2025 include the regulatory approval of vimseltinib in patients with tenosynovial giant cell tumor (TGCT); the finalization of the phase III INSIGHT trial, which aims to validate in the clinic the use of ctDNA to guide therapeutic decisions in GIST (NCT05734105); and the leadership of an international-expert panel that has established the role of next-generation sequencing (NGS) in sarcomas (Serrano et al, JAMA Oncol 2025).
Figure: From Cicala et al, JCO Precision Oncology 2025. The mutational landscape of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) is unknown given its rarity. As a consequence, there are no therapies specifically approved in this disease. We found that approximately one third of patients has actionable events in the PI3K/mTOR pathway, which are found particularly in metastatic samples. As a proof-of-concept, one of our patients with such alterations received off-label use of everolimus, achieving a long-lasting response of >55 months.
- Identification of critical molecular mediators of oncogenic signaling in sarcomas.
- Studying the patterns of chromosome instability (CIN) in sarcomas together with its role in tumor evolution and progression.
- Characterization of mechanisms of response and resistance to targeted therapies in sarcomas, including preclinical modelling and validation of therapeutic strategies for their translation to the clinic.
- Phase I to phase III studies for clinical drug development in sarcomas.
Group Leader
César Serrano
Oncologists
Carlo M. Cicala
Davide Romandini
Post-Doctoral Fellow
Pawel Sobczuk
Pre-Doctoral Fellows
Jon Ander Aguirre Carrillo
Marc Arbonés
Júlia Caparrós Mateos
David Gómez Peregrina
Yulia Kremlyakova
Gemma Mur Bonet
Iván Olivares Rivas
Tulio Silva
Senior Technician
Jordi Rosell Aluja
Graduate Student
Laia Conchillo Puigmolé
Nerea Garrido Pérez
Lian Shidong Porta Coll
Most Relevant Scientific Publications
- Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review. Serrano C, Bauer S, Blay JY, Casali PG, Cicala CM, Dei Tos AP, Digklia A, Gelderblom H, Italiano A, Jones RL, Kasper B, Kyriazoglou A, Le Loarer F, Martín-Broto J, Napolitano A, Rutkowski P, Stacchiotti S, Tap W, Thomas D, Thway K, Valverde C, van der Graaf WTA, Wardelmann E, Bovée JVMG. JAMA Oncol. 2025 Dec 1;11(12):1527-1537.
- Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe. Kyriazoglou A, Zając A, Valverde C, Czarnecka AM, Błoński P, Romagosa C, Seliga KA, Koulouridi A, Mala A, Wągrodzki M, Silva TM, Witczak M, Ługowska I, Rosińska M, Álvarez R, Aguirre M, Tysarowski A, Kokkali S, Georgoulias V, Serrano C, Rutkowski P, Boukovinas I. ESMO Open. 2025 Sep;10(9):105577.
- Many paths, one destination: Bridging the gap in cancer care. Sahai E, Wang H, Kok M, Wu CJ, Shen L, Carpten J, Serrano C, Venkataramani V. Cancer Cell. 2025 Apr 14;43(4):577-580.
- Targeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. Cicala CM, Matito J, Quindos M, Gómez-Peregrina D, Romero-Lozano P, Fernández-Suárez P, Valverde C, González M, Landolfi S, Pérez-Albert P, Gros L, Vivancos A, Serrano C. JCO Precis Oncol. 2025 Jan;9:e2400497.
- Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med. 2023 Nov;29(11):2689-2692.
- Serrano C, Martín-Broto J, Asencio-Pascual JM, López-Guerrero JA, Rubió-Casadevall J, Bagué S, García-Del-Muro X, Fernández-Hernández JÁ, Herrero L, López-Pousa A, Poveda A, Martínez-Marín V. 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192388.
- Serrano C, Bauer S, Gómez-Peregrina D, Kang YK, Jones RL, Rutkowski P, Mir O, Heinrich MC, Tap WD, Newberry K, Grassian A, Shi H, Bialick S, Schöffski P, Pantaleo MA, von Mehren M, Trent JC, George S. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. Ann Oncol. 2023 Jul;34(7):615-625.
- Pestana RC, Serrano C. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Front Oncol. 2023 Jan 18;12:1079909.
- Schaefer IM, DeMatteo RP, Serrano C. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15.
- Ravegnini G, Fosso B, Ricci R, Gorini F, Turroni S, Serrano C, Pilco-Janeta DF, Zhang Q, Zanotti F, De Robertis M, Nannini M, Pantaleo MA, Hrelia P, Angelini S. Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options. Cancer Sci. 2022 Aug;113(8):2590-2599.
- Manzano-Muñoz A, Yeste J, Ortega MA, Martín F, López A, Rosell J, Castro S, Serrano C, Samitier J, Ramón-Azcón J, Montero J. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy. NPJ Precis Oncol. 2022 Dec 1;6(1):90.
- García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. Oncogene. 2021 Dec;40(48):6614-6626.
- Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res. 2021 Dec 1;27(23):6333-6342.
- Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
- Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 Mar;145:132-142.
- Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a doubleblind, randomised, placebocontrolled, phase 3 trial. Lancet Oncol. 2020 Jul;21(7):923-934.
- Serrano C, George S. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clin Cancer Res. 2020 Oct 1;26(19):5078-5085.
Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowski P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S, George S. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 Jul;21(7):935-946. - Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Mar;120(6):612-620.
- Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib. Oncologist. 2019 May;24(5):680-687.
George S, Serrano C, Hensley ML, Ray-Coquard I. Soft Tissue and Uterine Leiomyosarcoma. J Clin Oncol. 2018 Jan 10;36(2):144-150. - Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20(22):5745-5755.
- George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014 Oct 15;120(20):3154-8.
- Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 1;33(22):e93-6.
All publications
- Proaño-Pérez E, Serrano-Candelas E, Guerrero M, Gómez-Peregrina D, Llorens C, Soriano B, Gámez-Valero A, Herrero-Lorenzo M, Martí E, Serrano C, Martin M. MITF regulates autophagy and extracellular vesicle cargo in gastrointestinal stromal tumors. Mol Biomed. 2025 Oct 31;6(1):92. doi: 10.1186/s43556-025-00329-9. PMID: 41168571; PMCID: PMC12575911.
- Serrano C, Bauer S, Blay JY, Casali PG, Cicala CM, Dei Tos AP, Digklia A, Gelderblom H, Italiano A, Jones RL, Kasper B, Kyriazoglou A, Le Loarer F, Martín-Broto J, Napolitano A, Rutkowski P, Stacchiotti S, Tap W, Thomas D, Thway K, Valverde C, van der Graaf WTA, Wardelmann E, Bovée JVMG. Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review. JAMA Oncol. 2025 Dec 1;11(12):1527-1537. doi: 10.1001/jamaoncol.2025.3608. PMID: 41100097.
- Mezquita L, Vicente-Herrero MT, Cruz P, de la Torre MVRÍ, Hidalgo-Coloma J, García LC, Gallego O, Calvo A, Martínez K, Pérez-Altozano J, Molina R, García-Pardo M, Gutiérrez-Sainz L, Moreno-Atahonero E, Oré-Arce M, Serrano C, Terradillos-García MJ, Valero MR, Reinoso-Barbero L, Rodríguez CA, Calvo-Cerrada B; SEOM – Environmental, Occupational Cancer Working Group, the AEEMT – Functional Group on Cancer, Work. SEOM-AEEMT consensus on occupational cancer and cancer-associated disability. Clin Transl Oncol. 2026 Mar;28(3):880-894. doi: 10.1007/s12094-025-04037-2. Epub 2025 Sep 16. PMID: 40956506.
- Kyriazoglou A, Zając A, Valverde C, Czarnecka AM, Błoński P, Romagosa C, Seliga KA, Koulouridi A, Mala A, Wągrodzki M, Silva TM, Witczak M, Ługowska I, Rosińska M, Álvarez R, Aguirre M, Tysarowski A, Kokkali S, Georgoulias V, Serrano C, Rutkowski P, Boukovinas I. Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe. ESMO Open. 2025 Sep;10(9):105577. doi: 10.1016/j.esmoop.2025.105577. Epub 2025 Sep 11. PMID: 40939238; PMCID: PMC12529307.
- Statz-Geary K, Elliott A, Bialick S, Serrano C, von Mehren M, Oberley M, Espejo-Freire AP, Barreto Coelho P, Costa PA, D’Amato GZ, Jonczak E, Trent JC, Montgomery E, Lombard D, Rosenberg A, Dhir A. DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers (Basel). 2025 Jun 12;17(12):1962. doi: 10.3390/cancers17121962. PMID: 40563612; PMCID: PMC12191036.
- Haddox CL, Papke DJ Jr, Serrano C. Leiomyosarcoma Therapeutic Approaches and Future Directions. Hematol Oncol Clin North Am. 2025 Aug;39(4):785-804. doi: 10.1016/j.hoc.2025.04.007. Epub 2025 May 22. PMID: 40410055.
- Cicala CM, Bauer S, Heinrich MC, Serrano C. Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease. Hematol Oncol Clin North Am. 2025 Aug;39(4):773-784. doi: 10.1016/j.hoc.2025.04.006. Epub 2025 May 13. PMID: 40368739; PMCID: PMC12416134.
- Nuñez Hernández I, Gómez Palmero C, Delgado JR, Nuño A, Sala González MÁ, González Ageitos A, Aguilar H, Ayala de Miguel P, Condori E, Díaz Beveridge R, Martínez García J, Marquina G, Varela-Pose V, Veas Rodríguez J, Serrano C. Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation. Oncologist. 2025 May 8;30(5):oyaf062. doi: 10.1093/oncolo/oyaf062. PMID: 40349140; PMCID: PMC12065942.
- Guerrero M, Proaño-Pérez E, Serrano-Candelas E, García-Valverde A, Carrillo-Rodríguez B, Rosell J, Serrano C, Martin M. Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth. Mol Ther Oncol. 2025 Apr 14;33(2):200983. doi: 10.1016/j.omton.2025.200983. PMID: 40343114; PMCID: PMC12060441.
- Sahai E, Wang H, Kok M, Wu CJ, Shen L, Carpten J, Serrano C, Venkataramani V. Many paths, one destination: Bridging the gap in cancer care. Cancer Cell. 2025 Apr 14;43(4):577-580. doi: 10.1016/j.ccell.2025.03.026. PMID: 40233716.
- Romandini D, Sobczuk P, Cicala CM, Serrano C. Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions. Curr Opin Oncol. 2025 Jul 1;37(4):358-364. doi: 10.1097/CCO.0000000000001145. Epub 2025 Apr 4. PMID: 40207474.
- Serrano C, Arregui M, Carrasco I, Hindi N, Martínez-Trufero J, Martínez-García J, Molina Á, Paisán A, Sánchez R, Sala MÁ. SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024). Clin Transl Oncol. 2025 Apr;27(4):1460-1471. doi: 10.1007/s12094-024-03842-5. Epub 2025 Feb 7. PMID: 39918719; PMCID: PMC12000159.
- Gómez-Puerto D, Cicala CM, Valverde C, Serrano C. Emerging treatments for sarcoma: from 2024 onward. Expert Opin Emerg Drugs. 2025 Feb 3:1-18. doi: 10.1080/14728214.2025.2460525. Epub ahead of print. PMID: 39874592.
- Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernández-Jover D, Gutierrez A, Serrano C, Monteagudo M, Letón R, Robledo M, Moura DS, Martin-Ruiz M, López-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023 Aug 9;22(1):127. doi: 10.1186/s12943-023-01832-9. PMID: 37559050; PMCID: PMC10413507.
- Pestana RC, Serrano C. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database. Front Oncol. 2023 Jan 18;12:1079909. doi: 10.3389/fonc.2022.1079909. PMID: 36741731; PMCID: PMC9890057.
- Di Vito A, Ravegnini G, Gorini F, Aasen T, Serrano C, Benuzzi E, Coschina E, Monesmith S, Morroni F, Angelini S, Hrelia P. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib. Pharmacol Ther. 2023 Aug;248:108475. doi: 10.1016/j.pharmthera.2023.108475. Epub 2023 Jun 10. PMID: 37302758.
- Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernández-Jover D, Gutierrez A, Serrano C, Monteagudo M, Letón R, Robledo M, Moura DS, Martin-Ruiz M, López-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023 Aug 9;22(1):127. doi: 10.1186/s12943-023-01832-9. PMID: 37559050; PMCID: PMC10413507.
- Ruiz-Demoulin S, Trenquier E, Dekkar S, Deshayes S, Boisguérin P, Serrano C, de Santa Barbara P, Faure S. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib. Int J Mol Sci. 2023 Apr 12;24(8):7138. doi: 10.3390/ijms24087138. PMID: 37108337; PMCID: PMC10138740.
- Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med. 2023 Nov;29(11):2689-2692. doi: 10.1038/s41591-023-02578-z. PMID: 37828359.
- He W, Xu L, Ding J, Song L, Yang W, Klooster I, Pilco-Janeta DF, Serrano C, Fang H, Jiang G, Wang X, Yu J, Ou WB. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166690. doi: 10.1016/j.bbadis.2023.166690. Epub 2023 Mar 13. PMID: 36921738.
- Proaño-Pérez E, Serrano-Candelas E, García-Valverde A, Rosell J, Gómez-Peregrina D, Navinés-Ferrer A, Guerrero M, Serrano C, Martín M. The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth. Cancer Gene Ther. 2023 Feb;30(2):245-255. doi: 10.1038/s41417-022-00539-1. Epub 2022 Oct 14. Erratum in: Cancer Gene Ther. 2022 Nov 18;: PMID: 36241703.
- Determinantes clínicos y moleculares de respuesta y progresión a la inhibición de KIT en pacientes con tumores del estroma gastrointestinal (GIST) con respuesta prolongada a Imatinib. Grupo Español de Investigación en Sarcomas (GEIS), Sociedad Española de Oncología Médica (SEOM), and Fundación Mari Paz Jiménez Casado.
- Modulating our ubiquitination machinery to innovate treatments and drug discovery in cancer. Asociación Española Contra el Cáncer– AECC (Spanish Association against Cancer).
- Perfiles de resistencia molecular a la inhibición de KIT/PDGFRA en tumores del estroma gastrointestinal. Asociación Española Contra el Cáncer – AECC (Spanish Association against Cancer).
- Centralization of pathological diagnosis and implementation of precision medicine strategies in sarcomas. Asociación Española Contra el Cáncer – AECC (Spanish Association against Cancer).
- Genomic determinants of tumor evolution and progression in sarcomas with simple karyotype. CRIS Foundation.
- Drivers of chromosome instability in karyotypically simple sarcomas: gastrointestinal stromal tumor as a paradigm. Instituto de Salud Carlos III.
- Yin-yang modulation of the ubiquitin-proteasome system to chart and treat RTK-driven neoplasms. TRIP-Clinics program (La Caixa Foundation and Generalitat de Catalunya).
The Sarcoma Translational Research Group receives support from the FERO Foundation through a Start-Up grant for the creation and consolidation of the group in the VHIO.
Related News
